Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christoph Funk

Showing results (1-10 of 42) with videos related to

Pageof 5
Sort By:
Expert Opinion on Drug Metabolism & Toxicology|April 25, 2008
The role of hepatic transporters in drug eliminationChristoph Funk
Archives of Toxicology|October 22, 2016
Current limitations and future opportunities for prediction of DILI from in vitroChristoph Funk, Adrian Roth
Journal of Pharmaceutical Sciences|March 24, 2010
Extrapolating in vitro metabolic interactions to isolated perfused liver: predictions of metabolic interactions between R-bufuralol, bunitrolol, and debrisoquineSami Haddad, Patrick Poulin, Christoph Funk
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 2, 2014
Response to "Breast cancer resistance protein substrate and inhibition evaluation: why, when, and how?"Agnès Poirier, Mohammed Ullah, Christoph Funk
Plos One|August 14, 2024
Finding common development paths in voluntary national reviews reporting on sustainable development goals using aspect-based sentiment analysisChristoph Funk, Elena Tönjes, Ramona Teuber, et al.
Plos One|November 2, 2023
Evaluating TCFD reporting-A new application of zero-shot analysis to climate-related financial disclosuresAlix Auzepy, Elena Tönjes, David Lenz, et al.
Current Opinion in Drug Discovery & Development|February 3, 2007
New strategies to address drug-drug interactions involving OATPsAgnés Poirier, Christoph Funk, Thierry Lavé, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 2, 2007
Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3Johannes Noé, Renée Portmann, Marie-Elise Brun, et al.
Chemistry & Biodiversity|November 26, 2009
Prediction of pharmacokinetic profile of valsartan in humans based on in vitro uptake-transport dataAgnès Poirier, Anne-Christine Cascais, Christoph Funk, et al.
Molecular Pharmaceutics|September 11, 2009
Mechanistic modeling of hepatic transport from cells to whole body: application to napsagatran and fexofenadineAgnès Poirier, Christoph Funk, Jean-Michel Scherrmann, et al.
Pageof 5

Showing results (1-10 of 42) with videos related to

Sort By:
Pageof 5
Expert Opinion on Drug Metabolism & Toxicology|April 25, 2008
The role of hepatic transporters in drug eliminationChristoph Funk
Archives of Toxicology|October 22, 2016
Current limitations and future opportunities for prediction of DILI from in vitroChristoph Funk, Adrian Roth
Journal of Pharmaceutical Sciences|March 24, 2010
Extrapolating in vitro metabolic interactions to isolated perfused liver: predictions of metabolic interactions between R-bufuralol, bunitrolol, and debrisoquineSami Haddad, Patrick Poulin, Christoph Funk
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 2, 2014
Response to "Breast cancer resistance protein substrate and inhibition evaluation: why, when, and how?"Agnès Poirier, Mohammed Ullah, Christoph Funk
Plos One|August 14, 2024
Finding common development paths in voluntary national reviews reporting on sustainable development goals using aspect-based sentiment analysisChristoph Funk, Elena Tönjes, Ramona Teuber, et al.
Plos One|November 2, 2023
Evaluating TCFD reporting-A new application of zero-shot analysis to climate-related financial disclosuresAlix Auzepy, Elena Tönjes, David Lenz, et al.
Current Opinion in Drug Discovery & Development|February 3, 2007
New strategies to address drug-drug interactions involving OATPsAgnés Poirier, Christoph Funk, Thierry Lavé, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 2, 2007
Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3Johannes Noé, Renée Portmann, Marie-Elise Brun, et al.
Chemistry & Biodiversity|November 26, 2009
Prediction of pharmacokinetic profile of valsartan in humans based on in vitro uptake-transport dataAgnès Poirier, Anne-Christine Cascais, Christoph Funk, et al.
Molecular Pharmaceutics|September 11, 2009
Mechanistic modeling of hepatic transport from cells to whole body: application to napsagatran and fexofenadineAgnès Poirier, Christoph Funk, Jean-Michel Scherrmann, et al.
Pageof 5